The application of specific blockade of coreceptors PD-1 and CTLA-4 in the context of cancer immunotherapy exhibits a substantial improvement in the prognostic outcomes for numerous populations of cancer patients, thereby significantly altering the landscape of cancer treatment (12–14). Here, PDCD1 is linked to cancer.